A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status

Protocol No
GOG-3082-ACRIVON-ACR-368-201
Phase
I/II
Summary

In this study, ACR-368 is being tested when it is given alone (called monotherapy) and when it is combined with low doses of a chemotherapy medication named gemcitabine (called combination study therapy). The main purpose of this study is to investigate how effective ACR-368 is in treating ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma in a population selected based on subjects who test OncoSignature Positive.

Description
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL